Literature DB >> 7986589

High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection.

M D Daniel1, G P Mazzara, M A Simon, P K Sehgal, T Kodama, D L Panicali, R C Desrosiers.   

Abstract

Eighteen rhesus monkeys were vaccinated with recombinant vaccinia viruses expressing SIVmac antigens in 3 separate rounds of experiments. Twelve of the monkeys were primed with a trivalent vaccinia virus recombinant expressing Gag, Pol, and Env polypeptides that can assemble into SIV pseudovirion particles and boosted with SIV particles in adjuvant. Four of the monkeys were primed with different vaccinia virus recombinants expressing env or gag+env followed by SIV particle boosts; two received vaccinia virus recombinants alone (env or env+gag). Despite the induction of vigorous immune responses, 17 of 18 rhesus monkeys became infected on challenge with a low dose of virulent SIVmac. The single protected animal was one of three challenged with homologous cloned SIV exactly matched to the clone used for construction of trivalent vaccinia virus recombinant and particles. Vaccination may have diminished SIV burdens and rates of CD4+ cell declines in some of the animals, but vaccinated/challenge/infected animals eventually developed fatal disease similar to control animals. These results highlight the extreme difficulty in achieving vaccine protection against virulent SIVmac infection even under idealized laboratory conditions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7986589     DOI: 10.1089/aid.1994.10.839

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  17 in total

1.  Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.

Authors:  P S Polacino; V Stallard; J E Klaniecki; S Pennathur; D C Montefiori; A J Langlois; B A Richardson; W R Morton; R E Benveniste; S L Hu
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus.

Authors:  R Shibata; C Siemon; S C Czajak; R C Desrosiers; M A Martin
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease.

Authors:  Rama Rao Amara; Kalpana Patel; Genevieve Niedziela; Pragati Nigam; Sunita Sharma; Silvija I Staprans; David C Montefiori; Lakshmi Chenareddi; James G Herndon; Harriet L Robinson; Harold M McClure; Francis J Novembre
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

4.  Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen.

Authors:  P Polacino; V Stallard; J E Klaniecki; D C Montefiori; A J Langlois; B A Richardson; J Overbaugh; W R Morton; R E Benveniste; S L Hu
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

5.  Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.

Authors:  J Benson; C Chougnet; M Robert-Guroff; D Montefiori; P Markham; G Shearer; R C Gallo; M Cranage; E Paoletti; K Limbach; D Venzon; J Tartaglia; G Franchini
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

6.  Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors.

Authors:  S Crotty; C J Miller; B L Lohman; M R Neagu; L Compton; D Lu; F X Lü; L Fritts; J D Lifson; R Andino
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

7.  Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation.

Authors:  R P Johnson; J D Lifson; S C Czajak; K S Cole; K H Manson; R Glickman; J Yang; D C Montefiori; R Montelaro; M S Wyand; R C Desrosiers
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

8.  Simian immunodeficiency virus DNA vaccine trial in macaques.

Authors:  S Lu; J Arthos; D C Montefiori; Y Yasutomi; K Manson; F Mustafa; E Johnson; J C Santoro; J Wissink; J I Mullins; J R Haynes; N L Letvin; M Wyand; H L Robinson
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

9.  Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine.

Authors:  S P Mossman; F Bex; P Berglund; J Arthos; S P O'Neil; D Riley; D H Maul; C Bruck; P Momin; A Burny; P N Fultz; J I Mullins; P Liljeström; E A Hoover
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

10.  Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys.

Authors:  Y Yasutomi; H L Robinson; S Lu; F Mustafa; C Lekutis; J Arthos; J I Mullins; G Voss; K Manson; M Wyand; N L Letvin
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.